Please login to the form below

Polyphor

This page shows the latest Polyphor news and features for those working in and with pharma, biotech and healthcare.

UK biotech bags €1.5m grant for new antibiotic class

a handful of startups that the fund has backed along with Entasis, Minervax, and Polyphor. ... And Swiss company Polyphor received around $11.5m to help it advance outer membrane protein targeting antibiotics (OMPTA) for resistant Gram-negative bacterial

Latest news

Roche drops superbug partnership with Polyphor

But adds inflammation research agreement with Proximagen. . Roche has opted to discontinue an alliance with Swiss biopharma company Polyphor to develop antibiotics for resistant infections. ... Rights to the drug revert to Polyphor, which insisted it
Roche buys GeneWeave to boost antibiotics portfolio

Like many of its peers in pharma, Roche ducked out of antibiotic research for many years but re-entered the sector two years ago with a $560m deal to license Polyphor'
Roche pays $1bn-plus for stake in genomics specialist

Roche had not been a player in the antibiotic sector for many years but returned to the fray in 2013 with a $560m deal development deal with Switzerland's Polyphor focusing
Cubist posts positive phase III antibiotic data

Meanwhile, Roche also made a return to antibiotics research after it acquired an antibiotic from Polyphor.
AZ strikes antibiotic deal with Singapore research unit

However, the latest announcement comes shortly after Roche signalled a return to anti-infectives development with the acquisition of a drug to treat Pseudomonas infections from Polyphor, raising hopes that big

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Pharma deals during February 2014

This follows Roche's deal with Polyphor worth up to $560m in November 2013.
Deal Watch table for November 2013

582. Polyphor / Roche. Licence. POL7080 which targets Pseudomonas aeruginosa, completed phase I.
Pharma deals during November 2013

With the highest headline value at $548m Roche announced its licence to Polyphor's experimental macrocycle antibiotic POL7080. ... As is often seen in such deals, Polyphor retains the option to co-promote an inhaled formulation of POL7080 in Europe.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Swiss Biotech Association appoints Michael Altorfer as CEO

Most recently he served at Polyphor as its CEO, and he has held many senior roles at the Swiss pharmaceutical company, including chief operating officer.
Kalina Scott joins Switzerland's Polyphor

Switzerland-based pharmaceutical company Polyphor has appointed Kalina Scott as its chief financial officer. ... Giacomo Di Nepi, CEO of Polyphor, said: “I am very pleased that Kalina has decided to join Polyphor.
Dr Engelbert Tjeenk Willink joins Allecra Therapeutics

Most recently serving as CMO for Polyphor, Hooftman (pictured left) has held several senior positions for the likes of Celltech Group plc and Chroma Therapeutics.
Polyphor appoints new chief medical and development officer

Giacomo Di Nepi, CEO at Polyphor, added: “I am very happy Debra joins Polyphor. ... Dr Baker succeeds Leon Hootftman, who leaves Polyphor to take a new position.

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Account Director: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Medical Editor: Competitive

Healthcare Lead Copywriter: Competitive

Healthcare Senior Account Manager: Competitive

Account Director – Creative Healthcare Communications: Competative

PMHub

Add my company

An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...